Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Gefitinib, erlotinib or afatinib are the current treatment for non-small-cell lung cancer (NSCLC) harboring an activating mutation of the epidermal growth factor receptor (EGFR), but less than 5% of patients achieve a complete response and the median progression-free survival is no longer than 12 mo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Codony-Servat, Carles, Codony-Servat, Jordi, Karachaliou, Niki, Molina, Miguel Angel, Chaib, Imane, Ramirez, Jose Luis, Gil, Maria de los Llanos, Solca, Flavio, Bivona, Trever G., Rosell, Rafael
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564566/
https://ncbi.nlm.nih.gov/pubmed/28521301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17625
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items